AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|
22.7 C
New York
Tuesday, September 1, 2026

Tag: product

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.

Curaleaf to Report Second Quarter 2026 Financial and Operational Results

STAMFORD, Conn., June 26, 2026 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of...

Curaleaf to Report Second Quarter 2026 Financial and Operational Results

STAMFORD, Conn., June 26, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of...

Minister Anandasangaree highlights launch of National Food Security Strategy

SCARBOROUGH, ON, June 26, 2026 /CNW/ - The Government of Canada is focused on building a stronger economy and making life more affordable for...

Blue Lizard® Brand Sunscreen Named First Official Sunscreen Partner of the Manning Passing Academy

A Partnership to Showcase the Importance of Sun Safety On and Off the FieldNASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Revance is proud to...

URBAN OUTFITTERS AND DOORDASH CELEBRATE THE CLASS OF 2030 WITH THE ULTIMATE GRADUATION CELEBRATION

The brands expand their partnership with a one-of-a-kind experience honoring a remarkable graduate and thousands of surprise deliveries for students nationwidePHILADELPHIA, June 26, 2026...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

From Cryptocurrency to Stocks: BulkQuant Expands AI Trading Robot Platform to Help Retail Investors Explore Automated Trading Strategies

London, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) --

BulkQuant, a fully managed AI trading robot platform, is expanding its automated trading ecosystem to help retail investors explore structured trading strategies across cryptocurrency, forex, and stock market environments.

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Alitheon FeaturePrint® Named “Overall Authentication Solution of the Year” in 2026 AI Breakthrough Awards Program

Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation
Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation

FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health

If finalized, rule would level the playing field between American and foreign businesses
If finalized, rule would level the playing field between American and foreign businesses

Autonomous Delivery Firm Neolix Expands European Presence as Retailers Fight Urban Logistics Costs

As FMCG and retail executives seek practical answers to last-mile economics, Neolix arrives with a commercial track recordVIENNA and FRANKFURT, Germany, June 26, 2026...

HOFSETH BIOCARE ASA: CONTEMPLATED PRIVATE PLACEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProduct